Drug Trial Radar · NCT06735391
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
516
Planned (sponsor's estimate)
Start
Oct 23, 2024
Primary completion
Sep 30, 2026
Study completion May 30, 2029
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.
Conditions
- Locally Advanced or Metastatic Non-squamous NSCLC
- Harboring EGFR Sensitive Mutations NSCLC
- Previously Untreated Systematically NSCLC
Interventions
JMT101Drug
JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.
OsimertinibDrug
EGFR TKI
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS assessed by the independent review committee (IRC) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Up to approximately 44 months after the first participant is enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat sen University Cancer Prevention and Treatment Center
Guangzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.